Evidence map›Paper›PMID 30585770›Full record

ArticleDiabetes technology & therapeutics2019

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Gregory P Forlenza, Orit Pinhas-Hamiel, David R Liljenquist, Dorothy I Shulman, Timothy S Bailey, Bruce W Bode, Michael A Wood, Bruce A Buckingham, Kevin B Kaiserman, John Shin and 3 more

Registry-linked trialAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04509362 (An 8-Day Initiation Protocol of Advanced Hybrid Closed Loop System In Children and Adolescents With Diabetes Type 1 On Multiple Daily Insulin Injection), which is not on this map. Cited by 86 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04509362 completednot on this mapstarted 2020, after this paper: background citation

An 8-Day Initiation Protocol of Advanced Hybrid Closed Loop System In Children and Adolescents With Diabetes Type 1 On Multiple Daily Insulin Injection

TypeobservationalSponsorSidra MedicineRan2020 to 2021Enrolled34ConditionsType 1 DiabetesArmsAdvanced Hybrid Closed Loop System
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Real-World Evidence of Automated Insulin Delivery System Use.Diabetes technology & therapeutics · 2024
    Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  17. Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  18. Article
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gregory P Forlenza1 Barbara Davis Center for Childhood Diabetes, Aurora, Colorado.
Orit Pinhas-Hamiel2 Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel.
David R Liljenquist3 Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho.
Dorothy I Shulman4 USF Diabetes Center, Morsani College of Medicine, University of South Florida, Tampa, Florida.
Timothy S Bailey5 AMCR Institute, Escondido, California.
Bruce W Bode6 Atlanta Diabetes Associates, Atlanta, Georgia.
Michael A Wood7 University of Michigan Medical School, Ann Arbor, Michigan.
Bruce A Buckingham8 Department of Pediatric Endocrinology, Stanford University, Stanford, California.
Kevin B Kaiserman9 SoCal Diabetes, Torrance, California.
John Shin10 Medtronic, Northridge, California.
Suiying Huang10 Medtronic, Northridge, California.
Scott W Lee10 Medtronic, Northridge, California.
Francine R Kaufman10 Medtronic, Northridge, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D).

methodsParticipants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week baseline run-in phase in Manual Mode followed by a 3-month study phase with Auto Mode enabled. Sensor glucose (SG), glycated hemoglobin (HbA

resultsAuto Mode was used a median of 81% of the time. From baseline to end of study, overall SG dropped by 6.9 ± 17.2 mg/dL (P < 0.001), HbA

conclusionIn-home use of MiniMed 670G system Auto Mode for 3 months by children with T1D, similar to MiniMed 670G system use by adolescents and adults with T1D, was safe and associated with reduced HbA

Indexed as

AdolescentBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsMaleTreatment OutcomeBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinAutomated insulin deliveryClosed-loop insulin deliveryGlucose variability.HbAPediatricType 1 diabetes

Identifiers

PMID30585770
PMCPMC6350071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.